Early antibody responses associated with survival in COVID19 patients |
| |
| Authors: | Zhao-Hua Zhou Sai Dharmarajan Mari Lehtimaki Susan L. Kirshner Steven Kozlowski |
| |
| Affiliation: | 1. Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration; Silver Spring, Maryland, United States of America;2. Office of Biostatistics, Office of Translational Science, Center for Drug Evaluation and Research, Food and Drug Administration; Silver Spring, Maryland, United States of America;The Peter Doherty Institute and Melbourne University, AUSTRALIA |
| |
| Abstract: | Neutralizing antibodies to the SARS CoV-2 spike proteins have been issued Emergency Use Authorizations and are a likely mechanism of vaccines to prevent COVID-19. However, benefit of treatment with monoclonal antibodies has only been observed in clinical trials in outpatients with mild to moderate COVID-19 but not in patients who are hospitalized and/or have advanced disease. To address this observation, we evaluated the timing of anti SARS-CoV-2 antibody production in hospitalized patients with the use of a highly sensitive multiplexed bead-based immunoassay allowing for early detection of antibodies to SARS-CoV-2. We found significantly lower levels of antibodies to the SARS-CoV-2 spike protein in the first week after symptom onset in patients who expired as compared to patients who were discharged. We also developed a model to characterize the relationship between each patient’s individual antibody level trajectory and eventual COVID 19 outcome which can be adapted into a prediction model with more data. |
| |
| Keywords: | |
|
|
